Role of NF-κB during Mycobacterium tuberculosis Infection. 2023

Nicole Poladian, and Davit Orujyan, and William Narinyan, and Armani K Oganyan, and Inesa Navasardyan, and Prathosh Velpuri, and Abraham Chorbajian, and Vishwanath Venketaraman
College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA.

Mycobacterium tuberculosis (M. tb) causes tuberculosis infection in humans worldwide, especially among immunocompromised populations and areas of the world with insufficient funding for tuberculosis treatment. Specifically, M. tb is predominantly exhibited as a latent infection, which poses a greater risk of reactivation for infected individuals. It has been previously shown that M. tb infection requires pro-inflammatory and anti-inflammatory mediators to manage its associated granuloma formation via tumor necrosis factor-α (TNF-α), interleukin-12 (IL-12), interferon-γ (IFN-γ), and caseum formation via IL-10, respectively. Nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) has been found to play a unique mediator role in providing a pro-inflammatory response to chronic inflammatory disease processes by promoting the activation of macrophages and the release of various cytokines such as IL-1, IL-6, IL-12, and TNF-α. NF-κB's role is especially interesting in its mechanism of assisting the immune system's defense against M. tb, wherein NF-κB induces IL-2 receptors (IL-2R) to decrease the immune response, but has also been shown to crucially assist in keeping a granuloma and bacterial load contained. In order to understand NF-κB's role in reducing M. tb infection, within this literature review we will discuss the dynamic interaction between M. tb and NF-κB, with a focus on the intracellular signaling pathways and the possible side effects of NF-κB inactivation on M. tb infection. Through a thorough review of these interactions, this review aims to highlight the role of NF-κB in M. tb infection for the purpose of better understanding the complex immune response to M. tb infection and to uncover further potential therapeutic methods.

UI MeSH Term Description Entries
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014376 Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS. Koch's Disease,Kochs Disease,Mycobacterium tuberculosis Infection,Infection, Mycobacterium tuberculosis,Infections, Mycobacterium tuberculosis,Koch Disease,Mycobacterium tuberculosis Infections,Tuberculoses
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB
D018664 Interleukin-12 A heterodimeric cytokine that plays a role in innate and adaptive immune responses. Interleukin-12 is a 70 kDa protein that is composed of covalently linked 40 kDa and 35 kDa subunits. It is produced by DENDRITIC CELLS; MACROPHAGES and a variety of other immune cells and plays a role in the stimulation of INTERFERON-GAMMA production by T-LYMPHOCYTES and NATURAL KILLER CELLS. Edodekin Alfa,IL-12,Natural Killer Cell Stimulatory Factor,Cytotoxic Lymphocyte Maturation Factor,IL 12,IL-12 p70,IL12,Interleukin 12,Interleukin-12 p70,Interleukin 12 p70

Related Publications

Nicole Poladian, and Davit Orujyan, and William Narinyan, and Armani K Oganyan, and Inesa Navasardyan, and Prathosh Velpuri, and Abraham Chorbajian, and Vishwanath Venketaraman
January 2021, Viruses,
Nicole Poladian, and Davit Orujyan, and William Narinyan, and Armani K Oganyan, and Inesa Navasardyan, and Prathosh Velpuri, and Abraham Chorbajian, and Vishwanath Venketaraman
October 2012, International journal of medical microbiology : IJMM,
Nicole Poladian, and Davit Orujyan, and William Narinyan, and Armani K Oganyan, and Inesa Navasardyan, and Prathosh Velpuri, and Abraham Chorbajian, and Vishwanath Venketaraman
January 2018, Cell cycle (Georgetown, Tex.),
Nicole Poladian, and Davit Orujyan, and William Narinyan, and Armani K Oganyan, and Inesa Navasardyan, and Prathosh Velpuri, and Abraham Chorbajian, and Vishwanath Venketaraman
January 2012, Frontiers in physiology,
Nicole Poladian, and Davit Orujyan, and William Narinyan, and Armani K Oganyan, and Inesa Navasardyan, and Prathosh Velpuri, and Abraham Chorbajian, and Vishwanath Venketaraman
August 2020, The Journal of infection,
Nicole Poladian, and Davit Orujyan, and William Narinyan, and Armani K Oganyan, and Inesa Navasardyan, and Prathosh Velpuri, and Abraham Chorbajian, and Vishwanath Venketaraman
May 2017, Future microbiology,
Nicole Poladian, and Davit Orujyan, and William Narinyan, and Armani K Oganyan, and Inesa Navasardyan, and Prathosh Velpuri, and Abraham Chorbajian, and Vishwanath Venketaraman
August 2009, Clinical and experimental immunology,
Nicole Poladian, and Davit Orujyan, and William Narinyan, and Armani K Oganyan, and Inesa Navasardyan, and Prathosh Velpuri, and Abraham Chorbajian, and Vishwanath Venketaraman
May 2017, Experimental cell research,
Nicole Poladian, and Davit Orujyan, and William Narinyan, and Armani K Oganyan, and Inesa Navasardyan, and Prathosh Velpuri, and Abraham Chorbajian, and Vishwanath Venketaraman
October 2020, Trends in microbiology,
Nicole Poladian, and Davit Orujyan, and William Narinyan, and Armani K Oganyan, and Inesa Navasardyan, and Prathosh Velpuri, and Abraham Chorbajian, and Vishwanath Venketaraman
January 2023, Current molecular medicine,
Copied contents to your clipboard!